Evidence map›Paper›PMID 37400797›Full record

ArticleBMC medicine2023

The Full Value of Vaccine Assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making.

Raymond Hutubessy, Jeremy A Lauer, Birgitte Giersing, So Yoon Sim, Mark Jit, David Kaslow, Siobhan Botwright

Abstract read
In one paragraph

Article in BMC medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed.

  1. Maternal Influenza Vaccine Reduces the Risk of Respiratory Syncytial Virus and Related Respiratory Hospitalizations in Early Infancy: An Epidemiological Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Raymond HutubessyImmunization, Vaccines and Biologicals Department, World Health Organization, 20 Avenue Appia, CH-1211, Geneva, Switzerland. hutubessyr@who.int.
Jeremy A LauerStrathclyde Business School, University of Strathclyde, Glasgow, UK.
Birgitte GiersingImmunization, Vaccines and Biologicals Department, World Health Organization, 20 Avenue Appia, CH-1211, Geneva, Switzerland.
So Yoon SimImmunization, Vaccines and Biologicals Department, World Health Organization, 20 Avenue Appia, CH-1211, Geneva, Switzerland.
Mark JitDepartment of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
David KaslowPATH Center for Vaccine Innovation and Access, Seattle, USA.
Siobhan BotwrightImmunization, Vaccines and Biologicals Department, World Health Organization, 20 Avenue Appia, CH-1211, Geneva, Switzerland.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundSeveral economic obstacles can deter the development and use of vaccines. This can lead to limited product options for some diseases, delays in new product development, and inequitable access to vaccines. Although seemingly distinct, these obstacles are actually interrelated and therefore need to be addressed through a single over-arching strategy encompassing all stakeholders.

methodsTo help overcome these obstacles, we propose a new approach, the Full Value of Vaccines Assessments (FVVA) framework, to guide the assessment and communication of the value of a vaccine. The FVVA framework is designed to facilitate alignment across key stakeholders and to enhance decision-making around investment in vaccine development, policy-making, procurement, and introduction, particularly for vaccines intended for use in low- and middle-income countries.

resultsThe FVVA framework has three key elements. First, to enhance assessment, existing value-assessment methods and tools are adapted to include broader benefits of vaccines as well as opportunity costs borne by stakeholders. Second, to improve decision-making, a deliberative process is required to recognize the agency of stakeholders and to ensure country ownership of decision-making and priority setting. Third, the FVVA framework provides a consistent and evidence-based approach that facilitates communication about the full value of vaccines, helping to enhance alignment and coordination across diverse stakeholders.

conclusionsThe FVVA framework provides guidance for stakeholders organizing global-level efforts to promote investment in vaccines that are priorities for LMICs. By providing a more holistic view of the benefits of vaccines, its application also has the potential to encourage greater take-up by countries, thereby leading to more sustainable and equitable impacts of vaccines and immunization programmes.

Indexed as

VaccinesDeveloping CountriesHumansImmunization ProgramsPolicy MakingVaccinationVaccinesEconomic evaluationsHealth technology assessmentImmunizationPublic healthResearch and developmentVaccines

Identifiers

PMID37400797
PMCPMC10318807

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.